
Join to view full profile
4488 Forest Park AveSte 160St. Louis, MO 63108
Phone+1 314-362-1408
Fax+1 314-286-1985
Dr. Schindler is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Suzanne Schindler is a clinical neurologist and neuroscientist committed to improving the diagnosis and treatment of Alzheimer disease. She completed the Medical Scientist Training Program in Neurosciences, a neurology residency, and a dementia fellowship at Washington University in St. Louis. Currently Dr. Schindler sees patients with memory concerns and coordinates clinical biomarker testing for the Washington University Memory Diagnostic Center. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center and facilitates many collaborative research projects. Key scientific contributions have been leading a seminal study of one of the first blood biomarkers of Alzheimer disease and developing novel approaches for understanding biomarker changes over the course of Alzheimer disease. Her current work is focused on the clinical validation of blood tests for Alzheimer disease and understanding the appropriate use of biomarker testing in the clinical diagnosis of dementia. Dr. Schindler also has a special interest in reducing healthcare disparities and improving access to diagnostic tests and treatments.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2008 - 2012
WashU MedicineClass of 2008
Certifications & Licensure
MO State Medical License 2012 - 2027
IL State Medical License 2021 - 2023
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2015-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2015-2017
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2015-2017
Publications & Presentations
PubMed
- Medical comorbidities of patients receiving amyloid-targeting treatments in a memory clinic.William J B Powell, Suzanne E Schindler, Martí Jiménez-Mausbach, Inez Y Oh, Anna Hofmann
Alzheimer's & Dementia. 2026-08-12 - Regional Cerebrospinal Fluid Motility as a Key Determinant of Soluble Amyloid-β Levels and Kinetics.Helia Hosseini, Aristeidis Sotiras, Chihiro Sato, Donald L Elbert, Braden Yang
Research Square. 2026-08-03 - Exploring longitudinal relationships among Alzheimer's disease biomarkers.Benjamin Saef, Kellen K Petersen, Katherine Volluz, Yan Li, Duygu Tosun
Alzheimer's & Dementia. 2026-08-01
Journal Articles
- Addressing Health Disparities Among Minority PopulationsSuzanne Schindler, MD, JAMA Neurology
Authored Content
- Blood Tests for Alzheimer’s Could Become RoutineMay 2024
Press Mentions
Blood Test “Clocks” Predict When Alzheimer’s Symptoms Will StartFebruary 19th, 2026
Blood Tests Reveal Obesity Rapidly Accelerates Alzheimer’s ProgressionDecember 10th, 2025
Blood Test Shows Obesity Speeds Alzheimer’s DevelopmentDecember 4th, 2025
Grant Support
- Staging Alzheimer disease with blood-based biomarkersWASHINGTON UNIVERSITY2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









